CTOs on the Move

Spectrum Plastics Group

www.spectrumplastics.com

 
We are leaders in medical plastics design, development & manufacture, with over 2,000 employees, and 20 manufacturing locations worldwide.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Bioxene

Bioxene is a Honolulu, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advanced Targeting Systems

Advanced Targeting Systems is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stevanato Group

Founded in 1949, Stevanato Group is committed to create systems, processes and services that guarantee the integrity of parenteral medicines. It is comprised of two operational divisions: Pharmaceutical Systems (Ompi and Balda brands): specialized in ready-to-use glass containers and bulk primary packaging (syringes, cartridges, vials, and ampoules); high quality and high precision plastic solutions for diagnostic, pharmaceutical and medical device applications. Engineering Systems (Spami, Optrel, InnoScan and SVM brands): specialized in glass forming technology, inspection systems, assembly, packaging machines and serialization solutions for the pharmaceutical industry. These two divisions enjoy a close, synchronous relationship, featuring daily exchanges which ensure that Stevanato Group has complete control over the entire production process, from purchasing the finest raw materials to offering exceptional after-sales customer service. The Group also benefits from the SG Lab activity that provides technical and analytical services on the potential interaction between the pharmaceutical product and the container.

PvP Biologics

PvP Biologics is developing an oral enzyme for the treatment of celiac disease. Our mission is to develop a highly-effective therapeutic product to reduce the burden of living with this disease. Towards this end, we are advancing a product candidate designed to break down the immuno-reactive parts of gluten in the stomach and thereby avoid the painful symptoms and damage done in the small intestine from accidental gluten ingestion. Affecting an estimated 2.4 million Americans, celiac disease is significantly more common than inflammatory bowel disease and is associated with acute gastrointestinal symptoms, malnutrition, and increased mortality. The disease is currently treated by a gluten-free diet, which is costly and challenging to maintain strict compliance. Many patients continue to report persistent symptoms despite adhering to a gluten-free diet. The technology was invented at the Institute for Protein Design at University of Washington and exclusively in-licensed by PvP Biologics. We have corporate offices in San Diego and research laboratories in Seattle.